-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
MoonLake Immunotherapeutics quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q2 2021 to Q3 2024.
- MoonLake Immunotherapeutics Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2024 was 62.9M shares, a 17.5% increase year-over-year.
- MoonLake Immunotherapeutics annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 49.1M shares, a 67.3% increase from 2022.
- MoonLake Immunotherapeutics annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 29.4M shares, a 91.8% decline from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)